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At a,-adrenergic receptors in isolated rat liver parenchymal cells, (-)-epinephrine is potent in eliciting a max- 
imal increase in glycogenolysis (K, = 24 nM). This contrasts with a lOO-fold lower affinity for the agonist 
at cr,-adrenergic receptors of intact hepatocytes determined from equilibrium competition assays with the 
cc,-adrenergic antagonist [3H]prazosin. We demonstrate here that agonists bind to a,-adrenergic receptors 
of intact liver cells initially with a markedly higher afftnity than under equilibrium conditions. When incuba- 
tions are performed for 15 s at 37°C the afftnity is more than lOO-fold higher than that obtained in equilibri- 
um (45 min) assays (IC,, = 28 f 3 vs 5300 f 400 nM for (-)-epinephrine and 32 f 3 vs 6 100 f 500 nM for 
(-)-norepinephrine). When incubations are performed at 4°C (150 min), high-affinity binding similar to that 
obtained in short-term incubations can also be demonstrated. In contrast, antagonist compete with similar 
afftnities in 15 s and 45 min assays, and their dissociation constants are not affected by changes in the 
incubation temperature. These results indicate that agonists bind to native a,-adrenergic receptors transient- 
ly wizh high afftnity. The conversion of receptors to a state of predominantly low affinity for agonists, which 
occurs rapidly and irreversibly with increasing incubation at 37”C, is inhibited at low incubation tempera- 
tures. It is suggested that the high-affinity configuration of the a,-adrenergic receptor for agonists observed 
in nonequilibrium experiments or at reduced incubation temperatures represents the physiologically relevant 
state of the a,-adrenergic receptor. 
cc,-Adrenergic receptor Isolated hepatocyte Glycogenolysis Nonequilibrium binding Conformational change 
Receptor affinity state 
1. INTRODUCTION 
Isolated rat hepatocytes have proved to be useful 
for the investigation of cur-adrenergic-receptor 
mediated effects [l-3]. Radioligand binding 
studies of adrenergic receptors conducted with in- 
tact cells, where the receptors remain in their 
native environment and attached to their effector 
systems, logically complement functional studies 
and should facilitate direct comparisons between 
functional assays and radioligand studies. 
However, such studies have revealed marked 
+ To whom correspondence should be addressed 
discrepancies at P-adrenergic receptors, where the 
affinity of agonists is several orders of magnitude 
lower in competition assays with radiolabeled an- 
tagonists than that predicted from their relative 
potency in eliciting maximal increases in CAMP 
[4,5]. A similar discrepancy is present in 
cut-adrenergic receptors in isolated hepatocytes, 
where agonists are potent stimulators of 
glycogenolysis [a]. 
We characterized the binding properties of 
agonists at at-adrenergic receptors of isolated 
hepatocytes under equilibrium and nonequilibrium 
conditions. Here we report on a phenomenon of 
transient high-affinity binding of agonists to 
at-adrenergic receptors of intact liver cells. 
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2. MATERIALS AND METHODS 
2.1. Preparation of hepatocytes 
Parenchymal liver cells were prepared by col- 
lagenase perfusion of livers from female Sprague- 
Dawley rats (180-240 g, Charles River Farm) 
maintained on standard Purina laboratory chow as 
described [7]. Cells were maintained in Dulbecco’s 
minimal essential medium (MA Bioproducts, 
Walkersville, MD) at a concentration of 2 x 
106/ml at 37°C prior to use. 
2.2. Radioligand binding studies with intact 
hepatocytes 
For binding assays, cells were washed twice with 
ice-cold PBS (10 mM, Dulbecco’s formula, pH 
7.4) at 50 x g for 5 min. In preliminary studies, 
several buffers [oxygenated Krebs-Ringer- 
bicarbonate (95% 02/5% COz) or DMEM with 
Earl’s salt solution] were employed and found to 
yield results identical to those obtained with PBS. 
Binding studies were performed in a total volume 
of 150 ~1 with a cell concentration of 2000001test 
tube [lo0 ~1 cell suspension, 25 ~1 [3H]prazosin 
(0.4-0.7 nM), and 25 ~1 of competing ligand, in 
triplicate]. ( - )-Epinephrine and ( - )-norepineph- 
rine were dissolved in buffer containing 0.1 mM 
ascorbic acid. When incubations were carried out 
at 4”C, cells and competing ligands were precooled 
separately for 15 min before the binding reaction 
was started. For nonequilibrium studies, a total 
assay volume of 1 ml was employed. The binding 
reaction was terminated by washing tubes with 4 x 
4 ml aliquots of PBS (25°C) onto 24 mm glass 
fiber filters (Schleicher and Schuell no.32), and un- 
bound ligand was separated by vacuum filtration. 
Filters were placed in 10 ml scintillation fluid 
(Hydrofluor) and counted in a liquid scintillation 
spectrometer (Beckman) with a counting efficiency 
of 56%. Data obtained from equilibrium radioli- 
gand binding studies were analysed with the non- 
linear computer-assisted weighted least-squares 
curve-fitting procedure, LIGAND, which fits the 
untransformed data directly to possible curves 
derived from the law of mass action using Mar- 
quard’s Algorithm [8]. Statistical analysis of 
‘goodness of fit’ for several models of ligand- 
receptor interaction (binding to one or more bind- 
ing sites) was performed as described by Munson 
and Rodbard [8]. For nonequilibrium binding ex- 
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periments, the ICSO (the concentration of com- 
peting ligand that inhibited 50% of specific bind- 
ing) and the percentage of high- and low-affinity 
sites for agonists were calculated with a 4-param- 
eter-logistic expression (‘twositehyp’) [9]. 
2.3. Chemicals 
[3H]Prazosin (80.9 Ci/mmol) was purchased 
from New England Nuclear. (-)-Epinephrine and 
( - )-norepinephrine were purchased from Sigma 
and prepared in buffer containing 0.1 mM ascor- 
bic acid. Prazosin and phentolamine were gifts 
from Pfizer Corp., Groton, CT and Ciba-Geigy, 
Summit, NJ, respectively. All other reagents were 
purchased from Sigma (St. Louis, MO). 
3. RESULTS 
3.1. Binding of tH]prazosin to intact hepatocytes 
As previously shown [7], binding of the specific 
aI-adrenergic antagonist [3H]prazosin to intact 
isolated hepatocytes was saturable, reversible and 
of appropriate specificity [lo]. Computer-assisted 
analysis of [3H]prazosin binding indicated interac- 
tion with a single class of sites (Bmax = 95500 + 
5500 receptors per cell) with a dissociation con- 
stant of 233 f 40 pM. 
3.2. Competition assays with agonists and 
antagonists in intact rat liver cells 
The affinity of agonists for al-adrenergic recep- 
tors of intact hepatocytes was investigated both 
under equilibrium conditions and under non- 
equilibrium conditions, where the ligand-receptor 
interaction follows initial-velocity conditions ([RL] 
Q [R][L]). Under the latter conditions, the ICso 
provides an estimate of the KD for rapidly 
equilibrating ligands, as detailed in [lo]. Competi- 
tion experiments were carried out with incubation 
times ranging from 0.25 to 45 min. The concentra- 
tion of radioligand used was between 1.5- and 
3-times the KD value. ‘Specific’ binding (binding 
inhibitable by 10e4 M (-)-epinephrine) was 
50-70% at 0.25 min and 70-90% at 45 min. At 
0.25 min, 5-10% of the binding that was observed 
after 45 min of incubation was present. When 
competition assays were performed for short in- 
cubation times (0.25 min), the resulting curves 
were biphasic and could be resolved into two dif- 
ferent classes of binding sites (fig.1). (-)- 
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Norepinephrine competed with [3H]prazosin for 
76% of all binding sites with an IGO of 32 + 3 nM 
and for 24% with an IGo of 6100 k 500 nM. Vir- 
tually identical results were obtained with (-)- 
epinephrine as the competing ligand (28 + 3 vs 
5300 + 400 nM, fig.2). With increasing incubation 
intervals, the competition curve for both agonists 
shifted progressively to the right (figs 1,2). The 
transition to predominant low-affinity binding oc- 
curred rapidly with a tr/z of approx. 1 min. At 
equilibrium (45 min incubation), inhibition curves 
were still biphasic; ( - )-norepinephrine inhibited 
79% of all [3H]prazosin-binding sites with a 
dissociation constant (Kd) of 2000 f 200 nM (n = 
5) and the remaining 21% with a Kd of 15 f 2 nM 
(fig.1). No further change in affinity occurred 
when incubations were continued for longer time 
periods. Similar proportions of high- and low- 
affinity sites were determined with (-)- 
epinephrine as competing ligand (fig.2). 
The non-equilibrium approach was validated in 
studies with cu-adrenergic antagonists. Phen- 
tolamine inhibited the binding of [3H]prazosin 
with similar affinity at 15 s or 45 min. At 
9 8 7 6 5 4 3 
- log [norepinephrine] , M 
Fig. 1. Inhibition of the binding of [3H]prazosin tointact 
liver cells by ( - )-norepinephrine under equilibrium and 
nonequilibrium conditions. Liver cells were incubated 
with [3H]prazosin (0.4 nM) and the indicated 
concentrations of (-)-norepinephrine for 0.25 (0) or 
45 (0) min at 37°C. Specific binding at 0.25 min was 
400-900 cpm (6-109’0 of that observed after 45 min of 
incubation). The results are expressed as the percentage 
of the radioligand bound at the indicated concentration 
of competing ligand. Points depicted are the means f SE 
from 3 experiments. 
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Fig.2. Inhibition of the binding of [3H]prazosin to intact 
liver cells by ( - )-ebinephrine at increasing incubation 
times. Liver cells were incubated with [3H]prazosin 
(0.4 nM) and the indicated concentrations of (-)- 
epinephrine for 0.25 (o), 0.5 (0), 1.0 (0) and 45 (m) 
min at 37’C. Points depicted are from an individual 
experiment, which is representative of 5 similar 
experiments. Percentages of high-affinity sites were 70 
(0.25 min), 52 (0.5 min), 60 (1 min) and 11% (45 min). 
The dashed line represents the predicted curve if all 
binding sites were in the high-affinity state. 
equilibrium, the inhibition curve for this ligand 
was shifted slightly (up to 3-fold, as compared to 
lOO-500-fold for agonists) to the right of that ob- 
tained in 15 s assays, depending on the concentra- 
tion of [3H]prazosin used [ll] (fig.3). At all in- 
cubation times, competition curves with phen- 
tolamine were indicative of an interaction with a 
single class of binding site. 
3.3. Functional studies in isolated hepatocytes 
To determine the K,,, for the al-adrenergic 
receptor mediated response, the activation of 
glycogen-phosphorylase a in isolated hepatocytes 
was determined in isolated hepatocytes under 
similar conditions to those used for the radioligand 
studies. Activation of glycogen-phosphorylase a 
upon addition of (-)-epinephrine was rapid in 
onset and near maximal in 30 s. Maximal stimula- 
tion was 1OOqo above basal activity of 15.1 f 
2.5 nmol [‘4C]glucose incorporated into glycogen/ 
min per mg protein. The K,,, value in these studies 
for (-)-epinephrine was 24 nM, which is in agree- 
ment with that determined by others in these cells 
[12,13] and, as shown in figs 1 and 2, with the KD 
estimates obtained in initial-velocity radioligand 
binding studies. 
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3.4. Effect of incubation temperature on the 100 I . 
affinity of adrenergic agonists and 
antagonists 
Previous studies have indicated that the decrease 
75 - 
in affinity for ,0-adrenergic receptors of intact cells 
is temperature-dependent [lo]. We therefore in- 
vestigated the interactions of agonists and an- 
tagonists with cYr-adrenergic receptors at reduced 
temperatures. Incubations were performed at 4°C 
for 150 min, a time period which proved to be suf- 
ficient to reach maximal binding. Under these con- 
ditions, (-)-epinephrine was approx. lOO-fold 
more potent than at 37°C (fig.4A). The competi- 
tion curves were best described by exclusive in- 
teraction of ( - )-epinephrine with high-affinity 
sites (Ku = 22 nM, n = 10). This value is similar 
to that obtained in short-time incubation studies. 
In additional studies, the affinity of clonidine, a 
partial agonist which causes 30-50% of 
50 - 
25 - 
o- .7' 
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Fig.3. Inhibition of the binding of [3H]prazosin to intact 
liver cells by phentolamine under equilibrium and 
nonequilibrium conditions. Liver cells were incubated 
with [3H]prazosin (0.7 nM) and the indicated 
concentrations of phentolamine for 0.5 (0) or 45 (0) 
min at 37°C. The results are expressed as percentage of 
the [3H]prazosin bound at the indicated concentrations 
of competing ligand. Points depicted are from an 
individual experiment, which is representative of 3 
similar experiments. With increasing incubation times, 
the competition curve for phentolamine shifts slightly to 
the right. The degree of the rightward shift was 
dependent on the concentration of radioligand used [ 1 I]. 
In most experiments, the rightward shift was only 
minimal, as concentrations of radioligand were used that 
were only slightly higher than the KD. In this experiment, 
a concentration of radioligand was used that was 3-fold 
higher than the KD, and the I&e is approx. 3-fold lower 
at equilibrium conditions than that at 15 s. 
- log [prarosin] , M 
Fig.4. Effect of temperature on the affinity of (- )- 
epinephrine (A) and non-radioactive prazosin (B) for 
cur-adrenergic receptors of intact hepatocytes. (A) 
Isolated hepatocytes were incubated with [3H]prazosin 
(0.7 nM) and increasing concentrations of (-)- 
epinephrine for 45 min at 37°C (m) or 150 min at 4°C 
(A). Points depicted are from an individual experiment, 
which is representative of 10 similar experiments. (B) 
Isolated hepatocytes were incubated with [3H]prazosin 
(0.7 nM) and increasing concentrations of nonradio- 
active prazosin for 45 min at 37°C (A---A) or 150 min 
at 4°C (n--~). The results are expressed as percentage 
of the [3H]prazosin bound at the indicated concentration 
of competing ligand. Points depicted are from an 
individual experiment, which is representative of 4 
similar experiments. 
epinephrine-induced stimulation of glycogenolysis, 
was also dependent on temperature, but increased 
only lo-fold at low incubation temperatures, as 
compared to lOO-fold increases observed for full 
agonists (not shown). In contrast, the affinity of 
antagonists was not changed by incubation at 
reduced temperatures (fig.4B). This finding was 
confirmed by Scatchard plots of saturation studies 
where the affinity for [3H]prazosin was found to 
be identical when incubations were performed at 
37°C /KD = 233 + 40 PM) or 4°C (KD = 260 + 
56 pM, n = 8). 
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4. DISCUSSION 
Here we present evidence that agonists bind to 
cur-adrenergic receptors of rat liver cells initially 
with a markedly higher affinity than that 
demonstrated under equilibrium conditions. This 
high-affinity binding, which can also be 
demonstrated when incubations are performed at 
4”C, is in good agreement with the K,,, obtained in 
functional studies. In contrast, the dissociation 
constant for agonists in intact cells obtained under 
equilibrium conditions appears to be misrepresen- 
tative of the true affinity, as it reflects only the 
endpoint of a conversion of receptors to a 
predominant state of low affinity. 
Our results are in complete agreement with find- 
ings previously obtained on /3-adrenergic receptors 
in intact cells, where a marked discrepancy exists 
between the potency of agonists to increase CAMP 
(Kact) and their affinity constant calculated from 
equilibrium competition radioligand binding 
studies [4,10,14-161. In all cell types examined, 
high-affinity binding of agonists could be 
demonstrated under initial velocity conditions, 
while few or no high-affinity sites could be 
detected at equilibrium [10,14-161. Thus, the 
results of equilibrium studies in intact cells con- 
ducted at 37°C are not predictive of the affinity for 
agonists under physiological conditions, i.e. in the 
first seconds of the hormone-receptor interaction. 
For ,&adrenergic receptors, there is now good 
evidence to support the conclusion that those bind- 
ing sites exhibiting high affinity for agonists 
represent ernary complexes of hormone, receptor 
and guanine-nucleotide-binding protein (G-pro- 
tein) [17]. At these receptors in intact cells, the 
kinetics of the decrease in agonist affinity followed 
a similar time course to the induction of a refrac- 
tory state [14]. It was thus suggested that the con- 
version to predominant low-affinity binding of 
agonists reflected an ‘uncoupling’ of the receptor 
from the adenylate cyclase system. As repeated 
stimulation with agonists does not lead to a 
diminution of ai-adrenergic receptor-mediated ef- 
fects on glycogenolysis and to a ‘downregulation’ 
of receptor number in rat liver [18-201, such a 
mechanism fails to explain the observed decrease 
in agonist affinity in our experiments. 
While the induction of a refractory state seems 
unlikely to be related to the phenomenon described 
in this communication, we believe that the decrease 
in affinity most likely reflects a conformational 
change within the receptor molecule. This was 
previously suggested by Weiland et al. [21] based 
on the thermodynamic analysis of agonist binding. 
These studies showed that the binding of agonists 
is associated with a large decrease in enthalpy, 
while antagonist binding is almost exclusively en- 
tropy driven. It seems possible that this conforma- 
tional change is involved in the information 
transfer across the cell membrane. Alternatively, it 
may represent a ‘shut-off’ mechanism to regulate 
adrenergic receptor-mediated effects independent 
of agonist off-rate. 
The cyi-adrenergic receptor is typically not 
‘coupled’ to adenylate cyclase. Following the in- 
itial observation by Goodhart et al. [22], that bind- 
ing to this receptor type can be modulated by 
guanine nucleotides, recent studies suggest hat a 
novel G-protein may be involved in the signal 
transduction pathway initiated by ai-adrenergic 
stimulation [23]. However, there is as yet no 
biochemical evidence that those binding sites ex- 
hibiting a high affinity for agonists represent er- 
nary complexes of hormone, receptor and G- 
protein. 
A high affinity for agonists when incubations 
were performed at low incubation temperature was 
also reported for cur-adrenergic receptors in a 
smooth muscle cell line [24], as well as for p- 
adrenergic receptors of intact cells [10,25]. It re- 
mains to be clarified why the transition to 
predominant low-affinity binding is inhibited at 
low incubation temperatures. It is tempting to 
speculate that the constraints imposed by low 
temperatures, such as increased membrane rigidity 
may prevent an internal rearrangement of the 
receptor molecule itself. 
In summary, our results demonstrate that 
agonists bind to native cui-adrenergic receptors of 
intact rat hepatocytes transiently with high affini- 
ty. Moreover, a conformational change of the 
agonist binding site, which seems to be fundamen- 
tally linked to the ‘efficacy’ of agonists, may be a 
common feature of all adrenergic receptor sub- 
types, independent of their different signal- 
transduction pathways. 
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